Filtered By:
Condition: Atrial Fibrillation
Countries: Japan Health

This page shows you your search results in order of date. This is page number 16.

Order by Relevance | Date

Total 333 results found since Jan 2013.

Device use for proximal anastomosis on ascending aorta in off-pump coronary artery bypass grafting.
CONCLUSIONS: Clinical safety of Device use in CABG comparable to No-touch for mortality and morbidity. Hemostasis may be a key issue for accomplishing higher level quality control when devices used in proximal anastomosis of CABG. PMID: 33065052 [PubMed - as supplied by publisher]
Source: The Annals of Thoracic Surgery - October 13, 2020 Category: Cardiovascular & Thoracic Surgery Authors: Saito A, Kumamaru H, Miyata H, Motomura N Tags: Ann Thorac Surg Source Type: research

Role of Remote Monitoring in Detection of Atrial Arrhythmia, Stroke Reduction, and Use of Anticoagulation Therapy 　- A Systematic Review and Meta-Analysis.
CONCLUSIONS: RM is effective for atrial arrhythmia detection in patients using wearable devices and for reducing the risk of stroke in patients with CIED. PMID: 33012748 [PubMed - as supplied by publisher]
Source: Circulation Journal - October 1, 2020 Category: Cardiology Authors: Jang JP, Lin HT, Chen YJ, Hsieh MH, Huang YC Tags: Circ J Source Type: research

Comparison of hospital length of stay of acute ischemic stroke patients with non-valvular atrial fibrillation started on rivaroxaban or warfarin treatment during hospitalization.
Conclusions: The rivaroxaban users had a 3-day shorter LOS-OAC after IPTW-adjustment. Using rivaroxaban was associated with a 4 to 5 days shorter LOS-OAC than using warfarin in patients with mild or moderate stroke, though treatment selection did not have a large impact in patients with severe stroke. PMID: 32936057 [PubMed - as supplied by publisher]
Source: Journal of Medical Economics - September 18, 2020 Category: Health Management Tags: J Med Econ Source Type: research

Secondary stroke prevention with apixaban in nonvalvular atrial fibrillation: A subgroup analysis of the STANDARD study
Data on independent risk factors for stroke recurrence in Japanese patients with nonvalvular atrial fibrillation are limited.
Source: Journal of Stroke and Cerebrovascular Diseases - August 15, 2020 Category: Neurology Authors: Masahiro Yasaka, Michiaki Umeyama, Hirohide Kataoka, Hiroshi Inoue Source Type: research

Antithrombotic therapy for stroke prevention in patients with atrial fibrillation in Japan.
Authors: Maruhashi T, Higashi Y Abstract INTRODUCTION: Stroke remains one of the major public health problems in Japan. The number of patients with atrial fibrillation (AF) has been steadily increasing with the aging of the Japanese population. Appropriate oral antithrombotic therapy is necessary to prevent AF-related stroke and bleeding complications. AREAS COVERED: The authors summarize the Japanese guidelines for antithrombotic therapy, as well as the current status of antithrombotic therapy, and future perspectives for antithrombotic therapy for patients with AF in Japan. EXPERT OPINION: Further improve...
Source: Expert Opinion on Pharmacotherapy - August 12, 2020 Category: Drugs & Pharmacology Tags: Expert Opin Pharmacother Source Type: research

Safety of Early Administration of Apixaban on Clinical Outcomes in Patients with Acute Large Vessel Occlusion
AbstractEarly administration of direct oral anticoagulants in patients with acute large vessel occlusion (LVO) and nonvalvular atrial fibrillation (NVAF) is a concern, as endovascular therapy (EVT) became highly utilized. We conducted a historical and prospective multicenter registry at 38 centers in Japan from July 2016 to February 2018. Patients aged ≥ 20 years with NVAF and acute LVO or stenosis who received apixaban within 14 days from onset were included. We compared patients who received apixaban<  48 h (Early group) and ≥ 48 h (Late group) after onset in terms of the primary outcome (a composite of ...
Source: Translational Stroke Research - August 6, 2020 Category: Neurology Source Type: research

Increased Incident Ischemic Stroke Risk in Advanced Kidney Disease: A Large-Scale Real-World Data Study
Conclusion: Although we found that OAC use was effective and recommended for patients with AF, advanced kidney disease is still an independent risk factor for IS/SE, even in patients taking OAC. Physicians should be aware of this risk and strictly control modifiable risk factors, regardless of OAC use.Am J Nephrol
Source: American Journal of Nephrology - July 29, 2020 Category: Neurology Source Type: research

Increased Incident Ischemic Stroke Risk in Advanced Kidney Disease: A Large-Scale Real-World Data Study.
CONCLUSION: Although we found that OAC use was effective and recommended for patients with AF, advanced kidney disease is still an independent risk factor for IS/SE, even in patients taking OAC. Physicians should be aware of this risk and strictly control modifiable risk factors, regardless of OAC use. PMID: 32726780 [PubMed - as supplied by publisher]
Source: American Journal of Nephrology - July 28, 2020 Category: Urology & Nephrology Authors: Maeda T, Nishi T, Funakoshi S, Tada K, Tsuji M, Satoh A, Kawazoe M, Yoshimura C, Arima H Tags: Am J Nephrol Source Type: research

Rationale, Design, and Baseline Characteristics of the BioProsthetic Valves with Atrial Fibrillation (BPV-AF) Study
ConclusionPatients enrolled into this study are typical of the wider Japanese AF/BPV population in terms of age and clinical history. Future data accruing from the observational period will contribute to future treatment recommendations and guide therapeutic decisions in patients with BPV and AF.Trial registrationClinicalTrials.gov Identifier: UMIN000034485
Source: Cardiovascular Drugs and Therapy - July 23, 2020 Category: Cardiology Source Type: research

Analysis of bioMARKer Distribution and Individual Reproducibility Under Rivaroxaban Treatment in Japanese Patients with Non-Valvular Atrial Fibrillation (R-MARK Study, CVI ARO2).
We reported the on-therapy range of rivaroxaban in a multicenter cohort. This range was consistent with that of a single-center cohort and was highly reproducible within three months in daily clinical practice. However, caution is necessary regarding several factors that may affect the intraindividual variation of PC-Riv. PMID: 32684604 [PubMed - as supplied by publisher]
Source: International Heart Journal - July 22, 2020 Category: Cardiology Tags: Int Heart J Source Type: research

Atrial Fibrillation With and Without Cardiovascular Risk Factors and Stroke Mortality.
CONCLUSIONS: AF was found to be an independent risk factor for stroke and total cardiovascular mortality even in individuals without other TCVRFs. PMID: 32554949 [PubMed - as supplied by publisher]
Source: Journal of Atherosclerosis and Thrombosis - June 20, 2020 Category: Cardiology Tags: J Atheroscler Thromb Source Type: research

Meta-analysis of efficacy and safety of new oral anticoagulants compared with warfarin in Japanese patients undergoing catheter ablation for atrial fibrillation
ConclusionsIn Japanese NVAF patients undergoing CA, NOACs have similar effects to warfarin in the prevention of stroke and systemic embolism. Moreover, NOACs were associated with a lower incidence of bleeding complications.
Source: Journal of Interventional Cardiac Electrophysiology - May 26, 2020 Category: Cardiology Source Type: research

Anti-Factor Xa Activity of Standard and Japan-Specific Doses of Rivaroxaban in Thai Patients With Non-Valvular Atrial Fibrillation.
CONCLUSIONS: A significantly higher proportion of Thai patients receiving the Japan-specific dose of rivaroxaban had anti-FXa activity at peak concentrations within the expected range. PMID: 32461505 [PubMed - as supplied by publisher]
Source: Circulation Journal - May 25, 2020 Category: Cardiology Authors: Wongcharoen W, Pacharasupa P, Norasetthada L, Gunaparn S, Phrommintikul A Tags: Circ J Source Type: research

Clinical implications of assessment of apixaban levels in elderly atrial fibrillation patients: J-ELD AF registry sub-cohort analysis
ConclusionsA high trough apixaban level in patients indicated for standard dose was not associated with adverse events, while a high apixaban level in patients indicated for a reduced dose was associated with bleeding requiring hospitalization.
Source: European Journal of Clinical Pharmacology - May 24, 2020 Category: Drugs & Pharmacology Source Type: research

Prognostic Value of Serum N-Terminal Pro-Brain Natriuretic Peptide Level over Heart Failure for Stroke Events and Deaths in Patients with Atrial Fibrillation.
Authors: Kuronuma K, Okumura Y, Morikawa T, Yokoyama K, Matsumoto N, Tachibana E, Oiwa K, Matsumoto M, Kojima T, Haruta H, Nomoto K, Sonoda K, Arima K, Kogawa R, Takahashi F, Kotani T, Ohkubo K, Fukushima S, Itou S, Kondo K, Chiku M, Ohno Y, Onikura M, Hirayama A, SAKURA AF Registry Investigators Abstract Atrial fibrillation (AF) and heart failure (HF) often coexist. The aims of this study were to explore the factors associated with the serum levels of N-terminal pro-brain natriuretic peptide (NT-proBNP), and the association between prognosis and a history of HF or the serum NT-proBNP level in Japanese patients wit...
Source: International Heart Journal - May 20, 2020 Category: Cardiology Tags: Int Heart J Source Type: research